Celltrion Wins Race For High-Concentration Adalimumab

Receives Positive CHMP Opinion For 100mg/ml Biosimilar To Humira

Man Winning Race
Celltrion expects to receive the first approval for a high-concentration adalimumab biosimilar • Source: Shutterstock

More from Products

More from Generics Bulletin